After finishing at $73.09 in the prior trading day, Cytokinetics Inc (NASDAQ: CYTK) closed at $72.24, down -1.16%. In other words, the price has decreased by -$0.85 from its previous closing price. On the day, 1903628 shares were traded.
Ratios:
Our goal is to gain a better understanding of CYTK by taking a closer look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 7.22 and its Current Ratio is at 6.12.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for the company, UBS on January 24, 2024, Downgraded its rating to Neutral and sets its target price to $92 from $61 previously.
On January 05, 2024, Morgan Stanley Downgraded its rating to Equal-Weight which previously was Overweight and also upped its target price recommendation from $60 to $90.
On November 09, 2023, Goldman started tracking the stock assigning a Buy rating and target price of $50.Goldman initiated its Buy rating on November 09, 2023, with a $50 target price.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Feb 14 when HENDERSON JOHN T sold 5,000 shares for $76.48 per share. The transaction valued at 382,400 led to the insider holds 42,632 shares of the business.
Blum Robert I sold 12,500 shares of CYTK for $960,625 on Feb 13. The President & CEO now owns 441,797 shares after completing the transaction at $76.85 per share. On Feb 06, another insider, Malik Fady Ibraham, who serves as the EVP Research & Development of the company, sold 32,605 shares for $79.30 each. As a result, the insider received 2,585,496 and left with 142,973 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, CYTK now has a Market Capitalization of 7.17B and an Enterprise Value of 7.22B. For the stock, the TTM Price-to-Sale (P/S) ratio is 940.65. Its current Enterprise Value per Revenue stands at 970.48 whereas that against EBITDA is -15.60.
Stock Price History:
Over the past 52 weeks, CYTK has reached a high of $110.25, while it has fallen to a 52-week low of $25.98. The 50-Day Moving Average of the stock is 76.66, while the 200-Day Moving Average is calculated to be 44.66.
Shares Statistics:
The stock has traded on average 3.73M shares per day over the past 3-months and 1.84M shares per day over the last 10 days, according to various share statistics. A total of 94.83M shares are outstanding, with a floating share count of 94.49M. Insiders hold about 3.63% of the company’s shares, while institutions hold 115.03% stake in the company. Shares short for CYTK as of Feb 15, 2024 were 13.83M with a Short Ratio of 3.70, compared to 13.75M on Jan 12, 2024. Therefore, it implies a Short% of Shares Outstanding of 14.10% and a Short% of Float of 23.80%.
Earnings Estimates
Its stock is currently analyzed by 14 different market analysts. On average, analysts expect EPS of -$1.12 for the current quarter, with a high estimate of -$0.86 and a low estimate of -$1.44, while EPS last year was -$1.38. The consensus estimate for the next quarter is -$1.11, with high estimates of -$0.83 and low estimates of -$1.36.
Analysts are recommending an EPS of between -$3.46 and -$6 for the fiscal current year, implying an average EPS of -$4.5. EPS for the following year is -$3.02, with 16 analysts recommending between -$1.53 and -$4.58.
Revenue Estimates
Based on 16 analysts’ estimates, the company’s revenue will be $176.27M in the next fiscal year. The high estimate is $583M and the low estimate is $5M. The average revenue growth estimate for next year is up 891.40% from the average revenue estimate for this year.
